Registered number: 11085607

CELEX ONCOLOGY INNOVATIONS LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2019

CELEX ONCOLOGY INNOVATIONS LIMITED
REGISTERED NUMBER: 11085607

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2019

	Note		2019 £		*2018 £*
Fixed assets					
Intangible assets	4		**219,593**		-
			219,593		-
Current assets					
Cash at bank and in hand	5	**75**		*2*	
		75		*2*	
Current liabilities					
Creditors: amounts falling due within one year	6	**(173,812)**		-	
Net current (liabilities)/assets			**(173,737)**		*2*
Total assets less current liabilities			**45,856**		*2*
Net assets			**45,856**		*2*
Capital and reserves					
Called up share capital			**400**		*2*
Share premium account			**49,700**		-
Profit and loss account			**(4,244)**		-
			45,856		*2*

STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2019

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 22 September 2020.

L J Cohen
Director

The notes on pages 3 to 5 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

1. General information

Celex Oncology Innovations Limited is a private company limited by shares and incorporated in England. The registered office is 9th Floor, The Royal Liver Building, Pier Head, Liverpool, L31JH.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

2.2 Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.3 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Amortisation will only commence once commercial production has started or when the developed product or service comes into use.

2.4 Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.5 Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

3. Employees

The average monthly number of employees, including the directors, during the year was as follows:

	2019	*2018*
	No.	*No.*
	6	*2*

4. Intangible assets

	Patents
	£
Cost	
Additions	**219,593**
At 31 December 2019	**219,593**
Net book value	
At 31 December 2019	**219,593**
At 31 December 2018	*-*

5. Cash and cash equivalents

	2019	*2018*
	£	*£*
Cash at bank and in hand	**75**	*2*
	75	*2*

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2019

6. Creditors: Amounts falling due within one year

	2019	*2018*
	£	*£*
Amounts owed to other participating interests	172,012	-
Accruals and deferred income	1,800	-
	173,812	-

7. Share capital

	2019	*2018*
	£	*£*
Allotted, called up and fully paid		
40,000 *(2018 - 200)* Ordinary shares of £0.01 each	400	*2*

During the year the company issued 39,998 ordinary shares of £0.01 for a total consideration of £50,100.

8. Post balance sheet events

Between the year end and the date of this report, Coronavirus and the COVID-19 pandemic emerged globally. For more detail regarding the directors' view of this event please refer to the Directors Report.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.